RedHill Biopharma Ltd. RDHL
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -59.62%
- 1 year
- -67.25%
- Market cap
- 3.70M
- Revenue (ttm)
- 3.71M
- Shares out
- 1.28M
- Forward P/E
- 210.67
- YTD return
- -59.62%
- 1-year return
- -67.25%
- Volume
- 23.57K
- Avg volume
- 2.08M
- Open
- 0.4395
- Previous close
- 0.4416
- Day's range
- 0.4101 – 0.4559
- 52-week range
- 0.38 – 1.60
- Beta
- 3.67
- Earnings date
- Oct 3, 2024
1Y -0.6600 (-61.11%)
Key statistics
- Enterprise value
- 76.44B
- PEG ratio
- 0.00
- Price / sales
- 2.18
- Price / book
- 121.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -28.40%
- Free cash flow
- -5.39M
- Total cash
- 7.28M
- Total debt
- 558.00K
- Return on equity
- -1708.61%
- Short % of float
- 0.49%
- 50-day average
- 7.70
- 200-day average
- 9.87
Next earnings
Oct 3, 2024
Expected Oct 3, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 3, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 1, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Jan 2, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
| Jun 12, 2023 | Mar 1, 2023 | 0.00 | 146.75 | — | — |
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- Website
- redhillbio.com
News
Redhill Biopharma Announced Confirmation Of RHB-204's Killing Capability On Mycobacterium Avium Subspecies Paratuberculosis And Its Comparability To RHB-104 MAP-Killing 
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
RedHill Biopharma’s Partner University Of Oklahoma Receives $2.9M In Funding From National Cancer Institute To Study, In Clinical Trials, Whether RedHill's Opaganib, Given After CAR T-Cell Therapy, May Help Immune Cells Fight Cancer More Effectively 
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma 
Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL) 
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results 
Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS) 
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq® 
12 Health Care Stocks Moving In Monday's Intraday Session
Your note
Sign in to keep a note on RDHL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federation Des Caisses Desjardins Du Quebec | 0.31% | 3,992 | 25.23K | Sep 29, 2024 |
| Rhumbline Advisers | 0.08% | 979 | 6.19K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.03% | 396 | 2.50K | Sep 29, 2024 |
| Morgan Stanley | 0.01% | 180 | 1.14K | Sep 29, 2024 |
| Capital Performance Advisors LLP | 0.00% | 5 | 31 | Sep 29, 2024 |
| Group One Trading, L.P. | 0.00% | 22 | 139 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 41 | 259 | Sep 29, 2024 |